Abstract
Since the introduction of reserpine by Kline in 1954 there have been relatively few studies of its use in schizophrenia and most of these have been uncontrolled. It is characteristic of these uncontrolled trials that when the results are assessed, they are described in glowing terms, and the percentage of patients reported as showing “moderate” or “marked” improvement is high.